Table of Contents Purpose of This PDQ Summary General Information Stage Information Early Stage Ovarian Low Malignant Potential Tumors
Advanced Stage Ovarian Low Malignant Potential Tumors Get More Information From NCI Changes to This Summary (12/21/2007) More Information
Purpose of This PDQ Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of ovarian low malignant potential tumors. This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board 1.
Information about the following is included in this summary:
- Epidemiology and diagnosis.
- Staging.
- Treatment options by cancer stage.
This summary is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Some of the reference citations in the summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a formal evidence ranking system 2 in developing its level-of-evidence designations. Based on the strength of the available evidence, treatment options are described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for reimbursement determinations.
This summary is available in a patient version 3, written in less technical language, and in Spanish 4. General Information
Tumors of low malignant potential (i.e., borderline tumors) account for 15% of all
epithelial ovarian cancers. Nearly 75% of these tumors are stage I at the time of
diagnosis. These tumors must be recognized because their prognosis and
treatment is clearly different from the frankly malignant invasive carcinomas.
A review of 22 series (953 patients) with a mean follow-up of 7 years revealed
a survival rate of 92% for patients with advanced-stage tumors, if patients with so-called
invasive implants were excluded. The cause of death was determined to be
benign complications of disease (e.g., small bowel obstruction), complications
of therapy, and only rarely (0.7%), malignant transformation.[1] In one
series, the 5-, 10-, 15-, and 20-year survival rates of patients with low
malignant potential tumors (all stages), as demonstrated by clinical life table
analysis, were 97%, 95%, 92%, and 89%, respectively.[2] In this series, mortality was stage
dependent: 0.7%, 4.2%, and 26.8% of patients with stages I, II, and III,
respectively, died of disease.[2] Another large study showed early stage, serous
histology, and younger age to be associated with a more favorable prognosis.[3]
In contrast to the excellent survival rates for early stage disease reported above, the Federation Internationale de Gynecologie et d’Obstetrique Annual Report (#21) included 529 patients with stage I tumors with a 5-year actuarial survival rate of 89.1%. Similarly, good survival was found in a
large prospective study.[4] Nonetheless, these survival rates are clearly in
contrast with the 30% survival rate for invasive tumors (all stages).
The less
common endometrioid tumor of low malignant potential should not be regarded as
malignant because it seldom, if ever, metastasizes. Malignant transformation
can, however, occur and may be associated with a similar tumor outside of the
ovary; such tumors are the result of either a second primary or rupture of the
primary endometrial tumor.[5]
References
-
Kurman RJ, Trimble CL: The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 12 (2): 120-7, 1993.
[PUBMED Abstract]
-
Leake JF, Currie JL, Rosenshein NB, et al.: Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 47 (2): 150-8, 1992.
[PUBMED Abstract]
-
Kaern J, Tropé CG, Abeler VM: A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 71 (5): 1810-20, 1993.
[PUBMED Abstract]
-
Zanetta G, Rota S, Chiari S, et al.: Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19 (10): 2658-64, 2001.
[PUBMED Abstract]
-
Norris HJ: Proliferative endometrioid tumors and endometrioid tumors of low malignant potential of the ovary. Int J Gynecol Pathol 12 (2): 134-40, 1993.
[PUBMED Abstract]
Stage Information
The Federation Internationale de Gynecologie et d’Obstetrique and the
American Joint Committee on Cancer have designated staging.[1,2]
Stage I
Stage I ovarian cancer is limited to the ovaries.
- Stage IA: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings.*
- Stage IB: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings.*
- Stage IC: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings.[1]
* [Note: The term, malignant ascites, is not classified. The presence of ascites does not affect staging unless malignant cells are present.]
Stage II
Stage II ovarian cancer is tumor involving one or both ovaries with
pelvic extension and/or implants.
- Stage IIA: Extension and/or implants on the uterus and/or fallopian tubes.
No malignant cells in ascites or peritoneal washings.
- Stage IIB: Extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings.
- Stage IIC: Pelvic extension and/or implants (stage IIA or stage IIB) with malignant cells in ascites or peritoneal washings.
Different criteria for allotting cases to stage IC and stage IIC have an impact on
diagnosis. To assess this impact, of value would be to know if
rupture of the capsule was (1) spontaneous or (2) caused by the surgeon; and, if
the source of malignant cells detected was (1) peritoneal washings or (2)
ascites.
Stage III
Stage III ovarian cancer is tumor involving one or both ovaries with
microscopically confirmed peritoneal implants outside the pelvis. Superficial liver metastasis equals stage III. Tumor is
limited to the true pelvis but with histologically verified malignant
extension to small bowel or omentum.
- Stage IIIA: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor).
- Stage IIIB: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension.
- Stage IIIC: Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis.
Stage IV
Stage IV ovarian cancer is tumor involving one or both ovaries with distant
metastasis. If pleural effusion is present, positive cytologic
test results must exist to designate a case to stage IV. Parenchymal liver metastasis equals
stage IV.
Ovarian low malignant potential tumors almost never reach stage IV.
References
-
Shepherd JH: Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96 (8): 889-92, 1989.
[PUBMED Abstract]
-
Ovary. In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 275-284.
Early Stage Ovarian Low Malignant Potential Tumors
The value of complete staging has not been demonstrated for early stage cases,
but the opposite ovary should be carefully evaluated for evidence of bilateral
disease. Although the impact of surgical staging on therapeutic management is
not defined, in a study, 7 of 27 patients with presumed localized disease were
upstaged following complete surgical staging.[1] In two other studies, 16%
and 18% of patients with presumed localized tumors of low malignant potential
were upstaged as a result of a staging laparotomy.[2,3] In one of these
studies, the yield for serous tumors was 30.8% compared with 0% for
mucinous tumors.[4] In another study, patients with localized
intraperitoneal disease and negative lymph nodes had a low incidence of
recurrence (5%), whereas patients with localized intraperitoneal disease and
positive lymph nodes had a statistically significantly higher incidence of
recurrence (50%).[5]
In early stage disease (stage I or II), no additional treatment is indicated for a
completely resected tumor of low malignant potential.[6] When a patient wishes
to retain childbearing potential, a unilateral salpingo-oophorectomy is
adequate therapy.[7,8] In the presence of bilateral ovarian cystic neoplasms,
or a single ovary, a partial oophorectomy can be employed when fertility is
desired by the patient.[9] Some physicians stress the importance of limiting ovarian
cystectomy to stage IA patients in whom the margins of the cystectomy specimens
are free of tumor.[4] In a large series, the relapse rate was higher with
more conservative surgery (cystectomy > unilateral oophorectomy > TAH, BSO);
differences, however, were not statistically significant, and survival was
nearly 100% for all groups.[5,10] When childbearing is not a consideration, a
total abdominal hysterectomy and bilateral salpingo-oophorectomy is appropriate
therapy. Once a woman has completed her family, most, but not all,[4]
physicians favor removal of remaining ovarian tissue as it is at risk of
recurrence of a borderline tumor, or even rarely, a carcinoma.[2,7]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage I borderline ovarian surface epithelial-stromal tumor 5 and stage II borderline ovarian surface epithelial-stromal tumor 6. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 7.
References
-
Yazigi R, Sandstad J, Munoz AK: Primary staging in ovarian tumors of low malignant potential. Gynecol Oncol 31 (3): 402-8, 1988.
[PUBMED Abstract]
-
Snider DD, Stuart GC, Nation JG, et al.: Evaluation of surgical staging in stage I low malignant potential ovarian tumors. Gynecol Oncol 40 (2): 129-32, 1991.
[PUBMED Abstract]
-
Leake JF, Rader JS, Woodruff JD, et al.: Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 42 (2): 124-30, 1991.
[PUBMED Abstract]
-
Piura B, Dgani R, Blickstein I, et al.: Epithelial ovarian tumors of borderline malignancy: a study of 50 cases. Int J Gynecol Cancer 2 (4): 189-197, 1992.
[PUBMED Abstract]
-
Leake JF, Currie JL, Rosenshein NB, et al.: Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 47 (2): 150-8, 1992.
[PUBMED Abstract]
-
Tropé C, Kaern J, Vergote IB, et al.: Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 51 (2): 236-43, 1993.
[PUBMED Abstract]
-
Kaern J, Tropé CG, Abeler VM: A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 71 (5): 1810-20, 1993.
[PUBMED Abstract]
-
Lim-Tan SK, Cajigas HE, Scully RE: Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 72 (5): 775-81, 1988.
[PUBMED Abstract]
-
Rice LW, Berkowitz RS, Mark SD, et al.: Epithelial ovarian tumors of borderline malignancy. Gynecol Oncol 39 (2): 195-8, 1990.
[PUBMED Abstract]
-
Casey AC, Bell DA, Lage JM, et al.: Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecol Oncol 50 (3): 316-22, 1993.
[PUBMED Abstract]
Advanced Stage Ovarian Low Malignant Potential Tumors
Patients with advanced disease should undergo a total hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, node sampling, and aggressive cytoreductive
surgery. Patients with stage III or IV disease with no gross residual tumor have
had a 100% survival rate in some series regardless of the follow-up
duration.[1,2] The 7-year survival rate of patients with gross residual
disease was only 69% in a large series [3] and appears to be inversely
proportional to the length of follow-up.[3]
For patients with more advanced-stage disease and microscopic or gross residual
disease, chemotherapy and/or radiation therapy are not indicated. Scant evidence exists that postoperative chemotherapy or radiation therapy alters the
course of this disease in any beneficial way.[1,3-6] In a study of
364 patients without residual tumor, adjuvant therapy had no effect on disease-free or corrected survival when stratified for disease stage.[7] Patients
without residual tumor who received no adjuvant treatment had a survival rate
equal to or greater than the treated groups. Currently, no controlled
studies have compared postoperative treatment with no treatment.
In a review of 150 patients with borderline ovarian tumors, the survival of
patients with a residual tumor of less than 2 cm was significantly
better than survival for those with a residual tumor from 2 to 5 cm and more than 5 cm.[8] Whether invasive implants imply a worse prognosis
remains an unsettled question. Some investigators have correlated invasive
implants with poor prognosis, [9] while others have not.[2,10] Some studies
have suggested that it may be possible to use DNA ploidy of the tumors to
identify those patients who will develop aggressive disease.[11,12] A study
could not correlate DNA ploidy of the primary serous tumor with survival but
found that aneuploid invasive implants were associated with a poor
prognosis.[13] Currently, no evidence indicates that treatment of patients with aneuploid
tumors would have an impact on survival. No significant association was found
between p53 and HER-2/neu overexpression and tumor recurrence or survival.[14]
In the face of clinical progression, further tumor reductive surgery followed
by chemotherapy is certainly indicated. If the symptom-free interval is long,
using chemotherapy after a secondary cytoreductive procedure is not advisable.
If, on the other hand, the disease symptomatically recurs rapidly, chemotherapy
may be beneficial. Reports have surgically documented the efficacy of
chemotherapy on some patients with microscopic or gross residual
disease.[15,16] A Gynecologic Oncology Group study used melphalan chemotherapy for patients with
progressive disease and used cisplatin for melphalan failures.[17]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage III borderline ovarian surface epithelial-stromal tumor 8 and stage IV borderline ovarian surface epithelial-stromal tumor 9. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 7.
References
-
Barnhill D, Heller P, Brzozowski P, et al.: Epithelial ovarian carcinoma of low malignant potential. Obstet Gynecol 65 (1): 53-9, 1985.
[PUBMED Abstract]
-
Bostwick DG, Tazelaar HD, Ballon SC, et al.: Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 58 (9): 2052-65, 1986.
[PUBMED Abstract]
-
Leake JF, Currie JL, Rosenshein NB, et al.: Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 47 (2): 150-8, 1992.
[PUBMED Abstract]
-
Casey AC, Bell DA, Lage JM, et al.: Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecol Oncol 50 (3): 316-22, 1993.
[PUBMED Abstract]
-
Tumors of the ovary: neoplasms derived from coelomic epithelium. In: Morrow CP, Curtin JP: Synopsis of Gynecologic Oncology. 5th ed. New York, NY: Churchill Livingstone, 1998, pp 233-281.
-
Sutton GP, Bundy BN, Omura GA, et al.: Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 41 (3): 230-3, 1991.
[PUBMED Abstract]
-
Kaern J, Tropé CG, Abeler VM: A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 71 (5): 1810-20, 1993.
[PUBMED Abstract]
-
Tamakoshi K, Kikkawa F, Nakashima N, et al.: Clinical behavior of borderline ovarian tumors: a study of 150 cases. J Surg Oncol 64 (2): 147-52, 1997.
[PUBMED Abstract]
-
Bell DA, Scully RE: Serous borderline tumors of the peritoneum. Am J Surg Pathol 14 (3): 230-9, 1990.
[PUBMED Abstract]
-
Michael H, Roth LM: Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer 57 (6): 1240-7, 1986.
[PUBMED Abstract]
-
Friedlander ML, Hedley DW, Swanson C, et al.: Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 6 (2): 282-90, 1988.
[PUBMED Abstract]
-
Kaern J, Trope C, Kjorstad KE, et al.: Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 38 (3): 452-7, 1990.
[PUBMED Abstract]
-
de Nictolis M, Montironi R, Tommasoni S, et al.: Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer 70 (1): 152-60, 1992.
[PUBMED Abstract]
-
Eltabbakh GH, Belinson JL, Kennedy AW, et al.: p53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 65 (2): 218-24, 1997.
[PUBMED Abstract]
-
Fort MG, Pierce VK, Saigo PE, et al.: Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 32 (3): 269-72, 1989.
[PUBMED Abstract]
-
Gershenson DM, Silva EG: Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 65 (3): 578-85, 1990.
[PUBMED Abstract]
-
Barnhill DR, Kurman RJ, Brady MF, et al.: Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 13 (11): 2752-6, 1995.
[PUBMED Abstract]
Get More Information From NCI
Call 1-800-4-CANCER
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your questions.
Chat online
The NCI's LiveHelp® 10 online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 9:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
- NCI Public Inquiries Office
- Suite 3036A
- 6116 Executive Boulevard, MSC8322
- Bethesda, MD 20892-8322
Search the NCI Web site
The NCI Web site 11 provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use our “Best Bets” search box in the upper right hand corner of each Web page. The results that are most closely related to your search term will be listed as Best Bets at the top of the list of search results.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
Find Publications
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator 12. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237), TTY at 1-800-332-8615. Changes to This Summary (12/21/2007)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Purpose of This PDQ Summary 13 as a section. More Information
About PDQ
Additional PDQ Summaries
Important:
This information is intended mainly for use by doctors and other health care professionals. If you have questions about this topic, you can ask your doctor, or call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). |